跳至主要内容
临床试验/CTRI/2025/09/094527
CTRI/2025/09/094527尚未招募2 期

Efficacy of Metoclopramide versus Lignocaine in reducing pain on propofol induction: A randomized controlled trial

Renduchintala Sravya Sunanda1 个研究点 分布在 1 个国家目标入组 158 人开始时间: 2025年10月1日最近更新:

试验速览

阶段
2 期
状态
尚未招募
发起方
入组人数
158
试验地点
1
主要终点
To evaluate for reduction of pain on propofol injection with metoclopramide versus lignocaine as pretreatment, using verbal rating scale

研究概览

简要总结

Propofol is the most commonly used intravenous anaesthetic agent, widely employed for the induction of general anaesthesia and for sedation during short procedures.

Metoclopramide as a prokinetic agent with antiemetic properties is a safe and effective option used before induction of anaesthesia .The pain-relieving properties of metoclopramide could be explained by the fact that serotonin/5-hydroxytryptamine (5-HT) is a biological amine in the brain and spinal cord . Studies indicate that 5-HT3 antagonists have sodium channel blocking action 15 times greater than that of lignocaine.

Lignocaine has been used to prevent propofol pain on injection, over the years.

We hypothesize that there will be a better reduction of pain on propofol induction with the use of metoclopramide as pretreatment compared to lignocaine.

研究设计

研究类型
Interventional
分配方式
Randomized
盲法
Participant, Investigator and Outcome Assessor Blinded

入排标准

年龄范围
18.00 Year(s) 至 70.00 Year(s)(—)
性别
All

入选标准

  • 1.Patients posted for elective surgeries under general anaesthesia 2.American Society of Anaesthesiologists(ASA) physical status 1 and 2 3.18 guage cannula on dorsum of hand.

排除标准

  • 1.Pregnant females
  • Patients posted for emergency procedures 3.Patients allergic to study drugs 4.Patients requiring rapid sequence intubation 5.Patients with extrapyramidal symptoms.

结局指标

主要结局

To evaluate for reduction of pain on propofol injection with metoclopramide versus lignocaine as pretreatment, using verbal rating scale

时间窗: 15 seconds

次要结局

  • To observe for adverse effects of the study drugs like itching & swelling, at the site of administration.(Patients will be followed up to 6 hours.)

研究者

发起方
Renduchintala Sravya Sunanda
申办方类型
Other [self]
责任方
Principal Investigator
主要研究者

Dr Renduchintala Sravya Sunanda

Kalinga Institute of Medical Sciences

研究点 (1)

Loading locations...

相似试验